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OBJECTIVES: Quality improvement initiatives in acute coro-
nary syndrome (ACS) such as CRUSADE have found marked
increase in treatment guideline adherence during the past several
years. This descriptive study used time-stamped data to examine
pharmacologic treatment and laboratory biomarker utilization
patterns in ACS patients who underwent percutaneous coronary
intervention (PCI). METHODS: The data source consisted of 19
hospitals throughout the U.S. that used time-stamp data from
January 2003–September 2004. ACS was identiﬁed in the dataset
using ICD-9 diagnosis codes for unstable angina and/or myocar-
dial infarction (MI). The time-stamp allowed more precise mea-
surement of drug administration and biomarker sampling.
Biomarker deﬁnition of MI was CK-MB >3 times upper limit of
normal, troponin I and myoglobin >1 times upper limit of
normal. RESULTS: A total of 6,282 ACS patients who had been
given clopidogrel were identiﬁed with adequate time-stamp
information. The most common recorded comorbid diagnoses
were ischemic heart disease 91.2%, hypertension 54.4%, lipid
disorder 57.9%, and diabetes 21.7%. Aspirin (ASA) plus clopi-
dogrel was received by 75.9% of patients and initiated on the
day of PCI in 88.3% of patients. The majority of initial ASA plus
clopidogrel administration was minus (-) 10 to plus (+) 14 hours
from PCI. GPIIb/IIIa inhibitors were received by 68.6% and
statins by 73% of patients, respectively during hospitalization.
Post-procedure (>8 hours after PCI) biomarker monitoring (CK-
MB, troponin I or myoglobin) was performed in 67.9% of
patients. The majority of testing was CK-MB or troponin I.
Results suggestive of MI were found in up to 67% of patients.
CONCLUSIONS: This novel examination of ACS treatment
using time-stamped data found ASA, clopidogrel; GPIIb/IIIa
inhibitors and statins were often used in this cohort. A wide
range of initial administration time for ASA plus clopidogrel
around PCI was found. Post-procedure biomarker monitoring
occurred frequently and was often positive.
PCV38
THIENOPYRIDINE THERAPY IN ACUTE CORONARY
SYNDROME PATIENTS RESIDING IN GERMANY
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OBJECTIVES: The European Society of Cardiology consensus
treatment guidelines in 2002 support use of clopidogrel in many
ACS patients for secondary prevention of cardiac events. This
study is to examine clopidogrel patterns of use in acute coronary
syndrome (ACS) patients in Germany. METHODS: The data
source was the IMS Health, Disease Analyzer Mediplus-German
database, containing approximately 4.2 million de-identiﬁed
patient records from approximately 1000 participating practices.
The analysis period was January 1, 2001-September 1, 2004.
The index ACS event was identiﬁed using ICD-10 codes for
unstable angina or acute myocardial infarction. Patients were
included if they had ≥3 months of data before and 6 months after
an index ACS event and ≥1 prescription for clopidogrel after the
event. RESULTS: Of the 28,688 patients included in the ACS
cohort, 748 had at least one clopidogrel prescription (2.6%) and
met inclusion criteria. Mean age was 67.5 years; 68% were male.
The mean number of recorded comorbidities was 7.4. High cho-
lesterol, hypertension, angina, ischemic heart disease, and dia-
betes were most common. The recorded mean length of clopi-
dogrel therapy was 41 days. 74% of patients stopped therapy,
deﬁned as not on clopidogrel 28-days prior to end of follow-up.
A gap in therapy, deﬁned as late reﬁlls >14 days apart, was seen
in 89%. Concomitant cardiovascular drug therapies included:
calcium channel blocker (20.3%), beta-blocker (69.1%) and
statin (64.7%). CONCLUSION: This descriptive study suggests
clopidogrel is underutilized in ACS patients and long-term adher-
ence to therapy was poor as demonstrated by stoppages or gaps
in therapy.
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THE EFFECT OF GENDER ON HEALTH-RELATED QUALITY
OF LIFE AFTER CORONARY STENT IMPLANTATION
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OBJECTIVE: The need for treatment of cardiac disease in
women can go unrecognised and access to appropriate health
care can be limited. We evaluated the effect of gender on changes
in long-term health-related quality of life (HRQoL) after coro-
nary stent implantation (CSI) in conventional treatment of coro-
nary artery disease (CAD). METHOD: In this prospective
comparative multi-centre cohort study in Germany, patients with
CAD undergoing coronary angioplasty were electively treated
with stents. Standardised questionnaires were completed by
patients at baseline, 3, 6, 12, and 18 months following angio-
plasty and documented patient health-related (SF-36) and
disease-speciﬁc (MacNew heart disease questionnaire) quality of
life, as well as clinical outcomes. RESULTS: From April until
August 2004, 103 women (16%, mean age 66, b11) und 546
men (mean age 64, b10) were treated with CSI. There were no
signiﬁcant differences in socio-demographic factors, cardiovas-
cular risk factors and severity of CAD. At baseline, all aspects
of HRQoL evaluated by SF-36 and MacNew were signiﬁcantly
poorer in women than in men (p = 0.004). Three months fol-
lowing stent implantation, the difference in improvement in the
SF-36 aspects of general health (p = 0.005), role emotional (p =
0.034) and the mental summary score (p = 0.027) was signiﬁ-
cantly greater in women than in men, although their actual
HRQoL remained signiﬁcantly lower in most aspects. After 6
months, the difference in improvement in women was signiﬁ-
cantly greater to baseline in the aspect of role emotional than
men (p = 0.019). Gender differences in improvement were not
demonstrated in the follow-up MacNew questionnaires. CON-
CLUSIONS: In comparison to men, baseline HRQoL in women
may be lower before receiving CSI treatment. However, three and
six months following implantation of a coronary stent, the 
difference in improvement in many aspects of HRQoL was
greater in women than in men. Women may have a wider range
of potential improvement after coronary stent implantation than
men.
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OBJECTIVES: Coronary heart disease (CHD) is nowadays the
most frequent cause of mortality and morbidity in industrialized
countries. In Europe it accounts for around two million deaths
